Lopinavir/ritonavir simplification strategy — Competitive Intelligence Brief

Lopinavir/ritonavir simplification strategy (Lopinavir/ritonavir simplification strategy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease inhibitor combination. Area: Infectious Disease.

marketed Protease inhibitor combination HIV protease Infectious Disease Small molecule

Target snapshot

Lopinavir/ritonavir simplification strategy (Lopinavir/ritonavir simplification strategy) — Fundación Huésped. A treatment strategy that simplifies HIV management by optimizing the dosing or administration of lopinavir/ritonavir, a protease inhibitor combination, to improve adherence and reduce pill burden.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lopinavir/ritonavir simplification strategy TARGET	Lopinavir/ritonavir simplification strategy	Fundación Huésped	marketed	Protease inhibitor combination	HIV protease
Lopinavir / Ritonavir	Lopinavir / Ritonavir	Baqiyatallah Medical Sciences University	marketed	HIV protease inhibitor	HIV protease
Darunavir / Ritonavir + Tenofovir / Emtricitabine	Darunavir / Ritonavir + Tenofovir / Emtricitabine	Juan A. Arnaiz	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Highly active antiretroviral therapy	Highly active antiretroviral therapy	PETHEMA Foundation	marketed	Antiretroviral combination therapy	HIV reverse transcriptase, HIV protease, HIV integrase (depending on regimen composition)
Lopinavir and Ritonavir Tablets	Lopinavir and Ritonavir Tablets	DualityBio Inc.	marketed	HIV protease inhibitor	HIV protease
Active comparator: DRV/cb	Active comparator: DRV/cb	Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud	marketed	HIV protease inhibitor with pharmacokinetic booster	HIV protease
AZT+3TC+IDV+RTV	AZT+3TC+IDV+RTV	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + PI)	HIV reverse transcriptase; HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protease inhibitor combination class)

1. Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · 1 drug in this class
2. Fundación Huésped · 1 drug in this class
3. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
4. University of Chicago · 1 drug in this class